Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells.

Autor:	Bravo-Filho V; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada.; Ophthalmology and Visual Sciences Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.; Ophthalmology Department, Fundação Altino Ventura, Recife, PE, Brazil., Logan P; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada., Zoroquiain P; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada., Aldrees S; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada., Vilà N; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada., Oweida A; Division of Radiation Oncology, McGill University, Montreal, Quebec, Canada., Belfort Neto R; Ophthalmology and Visual Sciences Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil., Burnier MN Jr; The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada.; Ophthalmology and Visual Sciences Department, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	Arquivos brasileiros de oftalmologia [Arq Bras Oftalmol] 2019 Jan-Feb; Vol. 82 (1), pp. 38-44. Date of Electronic Publication: 2018 Nov 01.
DOI:	10.5935/0004-2749.20190004
Abstrakt:	Purpose: To evaluate the effects of ranibizumab and amfenac in human uveal melanoma cell lines and to explore the ability of these compounds to sensitize uveal melanoma cells to radiation therapy. Methods: The 92.1 human uveal melanoma cell line was cultured and subjected to the proposed treatment (ranibizumab, amfenac, and a combination of both). Proliferation, migration, and invasion assays of the 92.1 uveal melanoma cell line were assessed after pretreatment with ranibizumab (125 mg/mL), amfenac (150 nM), or a combination of both. In addition, proliferation rates were assessed after treatment with ranibizumab and amfenac, and the cells were subsequently exposed to various radiation doses (0, 4, and 8 Gy). Results: Proliferation assay: cells treated with a combination of ranibizumab and amfenac had lower proliferation rates than controls (p=0.016) and than those treated with only ranibizumab (p=0.033). Migration assay: a significantly lower migration rate was observed in cells treated with amfenac than the control (p=0.014) and than those treated with ranibizumab (p=0.044). Invasion assay: there were no significant differences among the studied groups. Irradiation exposure: in the 4 Gy dose group, there were no significant differences among any groups. In the 8 Gy dose group, treatment with ranibizumab, amfenac, and their combination prior to application of the 8 Gy radiation led to a marked reduction in proliferation rates (p=0.009, p=0.01, and p=0.034, respectively) compared with controls. Conclusion: Combination of ranibizumab and amfenac reduced the proliferation rate of uveal melanoma cells; however, only amfenac monotherapy significantly decreased cell migration. The radiosensitivity of the 92.1 uveal melanoma cell line increased following the administration of ranibizumab, amfenac, and their combination. Further investigation is warranted to determine if this is a viable pretreatment strategy to render large tumors amenable to radiotherapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu